NCT01718639

Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

Randomized, Controlled, Single-blind, Three-way Crossover Clinical Investigation to Evaluate Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: InQpharm Group · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study is a randomized, placebo-controlled, single-blind, three-way crossover clinical trial to evaluate safety and efficacy of IQP-LH-101 (tablet form and liquid form) in postprandial heartburn. The null hypothesis is that there is no difference between IQP-LH-101 and the placebo in terms of efficacy for postprandial heartburn treatment.

Conditions

• Postprandial Heartburn

Interventions

Type	Name	Description
DEVICE	IQP-LH-101 tablet	Oral medical device in the form of a chewable tablet
DEVICE	IQP-LH-101 liquid	Oral medical device in the form of a liquid
OTHER	Placebo

Timeline

• Start date: 2012-10-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2012-10-31
• Last updated: 2013-03-11

Locations

1 site across 1 country: Germany